

**Abstract CODE : A002**

**TYPE : ORAL PRESENTATION**

**CATEGORY : INTERVENTIONAL ONCOLOGY**

**TITLE**

The Five Years Survival Analysis of TACE and RFA Combined Treatment for the Patients with Hepatocellular Carcinoma

**BACKGROUND**

The aim of this study was to investigate the prognostic value of radiofrequency ablation (RFA) with transcatheter arterial chemoembolization (TACE) in early and middle stages of hepatocellular carcinoma (HCC) patients with tumor size up to 5cm. Outcomes after TACE and RFA treatment in primary hepatocellular carcinoma Analysis of the influencing factors and TACE in hepatocellular carcinoma and to study the quality of life by adjunct RFA treatment.

**METHODS**

From 2018 to 2022 in this retrospective study analyzed data on 425 patients with early and middle stages HCC. According to treatment procedure, the patients were divided into the TACE group (n=67), RFA group (n=255) and the TACE+RFA group (n=125). The overall survival (OS) and progression-free survival (PFS) in the 3 groups were analyzed and compared between groups.

**RESULT**

: In total number of 425 patients 1-, 3-, and 5- years for all cases were calculated and the survival rate was 89.2%, 68.7%, and 51.3%. In RFA group (n=233) 1-, 3-, and 5-years survival rate of patients after RFA treatment were 92.1%, 77.3%, and 62.6%, in TACE group 1-, 3-, and 5-years survival after TACE (67) treatment were 87.5%, 62.9%, and TACE and RFA (125) group 1-, 3-, and 5-years survival after combined treatments were 96.2%, 79.4%, was 65.5%.

**CONCLUSIONS**

Combined RFA and TACE was associated with significantly better survival than TACE alone on long-term follow-up. Patients with tumors 3 cm or smaller more effective and safer using the RFA treatment.

**AUTHOR**

Erdenebulgan Batmunkh

**CO-AUTHOR**

Dr. Gantulga Vanchinsuren

Dr. Zayabat Badrakhzul

Dr. Baasanjav Narangerel

Dr. Batmunkh Myagmar

Dr. Bat-Amgalan Ganzorig